• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Faron dealing ordinary shares on AIM market

Faron dealing ordinary shares on AIM market

November 17, 2015
CenterWatch Staff

Turku, Finland-based Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has begun dealings in its ordinary shares on the AIM market of the London Stock Exchange.

The move follows a successful placing and subscription for more than 3.8 million new ordinary shares, raising £10 million at a price of 260p per ordinary share.

Dr. Markku Jalkanen, chief executive officer of Faron, said, “Faron’s fundraising and admission to AIM is an important landmark for the company. We believe that the support shown by both new and existing shareholders demonstrates a strong understanding of the value of our late-stage product Traumakine, in development for the treatment of acute respiratory distress syndrome. Currently there are no approved pharmacological treatments for this life threatening medical condition.

“Admission to AIM provides a great opportunity to strengthen our business and support our objective of progressing our lead program through a pan-European phase III trial, and the development of our preclinical cancer immunotherapy candidate, Clevegen. We look forward to reporting on the company’s continuing progress as an AIM-quoted company and would like to welcome and thank our investors for their involvement.”

Cairn Financial Advisers is acting as nominated adviser to Faron. Whitman Howard is acting as broker and book-runner to the company, while Rx Securities is acting as equity adviser.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing